MSCT-guided percutaneous cryoablation combined with 125I-seed implantation for the treatment of lung cancer: an observation of short-term efficacy

Objective: To evaluate the short-term efficacy of MSCT-guided percutaneous argon-helium cryoablation combined with 125I-seed implantation in treating lung cancer, and to discuss the clinical feasibility and safety of this technique. Methods: Under the guidance of MSCT 3D-reconstruction imaging,percutaneous argon-helium cryoablation was performed in 51 patients with advanced lung cancer, which was followed by 125I-seed implantation with the help of treatment plan system (TPS). The 125I seeds were implanted into the edge and the un-frozen area of the tumor according to the therapeutic dosage and distribution calculated by TPS. After the procedure MSCT 3D-reconstruction imaging was carried out to check the location of the implanted 125I seeds. Both plain and contrast-enhanced CT scans of the chest were conducted 1, 2, 3 and 6 months after the treatment. The therapeutic results were analyzed and evaluated. Results: One, 2, 3 and 6 months after the treatment favorable improvement was seen in 9.8%, 19.6%, 56.9% and 46.0% of patients respectively, with the total effective rate of 31.4%, 62.8%, 98.0% and 92.0% respectively. Conclusion: For the treatment of lung cancer MSCT-guided percutaneous puncture argon-helium cryoablation ablation combined with 125I-seed implantation is a safe and minimally-invasive technique with fewer complications and reliable short-term effect. Therefore, it is of value to popularize this therapy in clinical practice. (authors)